Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study.

"Declaration Of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the Health Science and Technology Plan Project of Zhejiang (2021KY1149) and the Bethune Medical Science Research Foundation (B19083FT)."

"This prospective, single-arm, phase II clinical trial was registered with the Chinese Clinical Trial Registry (number: ChiCTR 1900027769). Eligible patients with multiple BMs from NSCLC without targetable driver mutations who failed to respond to at least first-line chemotherapy received anlotinib (12 mg/day, day 1-14 of 21 days a cycle, 2 cycles) combined with WBRT. The BM of the enrolled patients were either advanced or newly identified after receiving cytotoxic systemic therapy regimens. The cytotoxic regimen for nonsquamous NSCLC was cisplatin or carboplatin combined with pemetrexed or paclitaxel, while that for squamous cell NSCLC was gemcitabine combined with cisplatin or carboplatin. All patients completed 4 to 6 cycles of chemotherapy."